The Critical Role of Power in Artificial Pancreas Systems

Artificial pancreas systems, also known as closed-loop insulin delivery systems, represent one of the most significant advances in diabetes management over the past decade. These devices continuously monitor interstitial glucose levels via a continuous glucose monitor (CGM) and automatically adjust insulin delivery through an insulin pump, mimicking the function of a healthy pancreas. This closed-loop operation demands a constant, reliable power supply—not only to run the sensor and pump motors but also to power wireless communication between components, onboard algorithms, safety checks, and user interfaces. Any interruption in power, even for a few minutes, can lead to loss of glycemic control, potential hypoglycemia or hyperglycemia, and device malfunction. As these systems become smaller, more discreet, and more integrated into daily life, the need for innovative wearable power sources that offer extended run times, compact form factors, and user-friendly recharging has become a top priority for device manufacturers and researchers alike.

Power Consumption Realities in Closed-Loop Devices

Modern artificial pancreas systems typically combine several subsystems, each with its own power profile. The CGM component, including the electrochemical sensor, transmitter, and antenna, may draw anywhere from 50 to 200 microwatts in steady state, with peaks during data transmission. The insulin pump includes a micro-motor and piston that can draw several hundred milliwatts during a bolus delivery, though the average power over time is lower. The control algorithm, often running on a dedicated microcontroller or a smartphone, adds computational load. Additionally, many systems incorporate safety features such as redundant processors, vibration motors for alerts, and backup batteries for fail-safe operation. Together, these elements impose a power demand of roughly 300 to 1000 milliwatts on average, with peak demands that can be significantly higher. For a device that must operate continuously for days or even weeks without recharging, energy storage capacity of at least 10 to 30 watt-hours is common—attaining this in a wearable form factor that is comfortable, flexible, and safe is the central engineering challenge.

Breakthroughs in Wearable Power Storage and Generation

Recognizing the limitations of conventional rigid lithium-ion cells in medical wearables, research teams and companies are pursuing multiple parallel paths to power the next generation of artificial pancreas devices. The following innovations represent the most promising directions currently under development or early commercialization.

Flexible Thin-Film Batteries

Flexible thin-film batteries are manufactured using solid-state electrolyte layers and thin electrode films deposited on flexible substrates such as polymer foils or textiles. Unlike traditional pouch cells, these batteries can bend, twist, and conform to the curvature of the human body without delamination or capacity loss. Companies like Jenax and Imprint Energy have demonstrated cells with energy densities approaching 200 Wh/L while maintaining flexibility over thousands of bending cycles. For an artificial pancreas patch worn on the abdomen or arm, a thin-film battery can be integrated directly into the device housing, eliminating the need for a separate battery compartment and reducing overall thickness. Recent innovations include lithium-polymer variants with printable electrodes and zinc-based chemistries that avoid flammable organic electrolytes, improving safety for medical applications. Clinical evaluations of prototype devices show that flexible batteries can provide at least 7 days of continuous operation with a single charge, a substantial improvement over earlier rechargeable systems that lasted only 24 to 48 hours.

Energy Harvesting from the Body and Environment

One of the most elegant solutions to the power challenge is to scavenge energy from the wearer’s own body or the surrounding environment, reducing or eliminating the need for external charging. Several modalities are under active investigation:

Kinetic Energy Harvesting

Piezoelectric and electromagnetic generators can convert body motion into electrical energy. Small devices embedded in an artificial pancreas patch or worn on a belt can capture energy from walking, arm movements, or even breathing. Research from the University of California San Diego demonstrates a flexible piezoelectric harvester that generates up to 1 mW from normal walking gaits—enough to power a low-power CGM transmitter but still insufficient for the entire system. Combining multiple harvesters or integrating them with supercapacitors for burst power delivery is a promising approach. Triboelectric nanogenerators (TENGs), which generate charge from sliding contact between materials, have also been tested. A 2023 study published in Nature Communications reported a skin-attachable TENG that produced up to 5 mW under typical motion, though long-term durability and signal conditioning remain engineering hurdles.

Thermal Energy Harvesting

Thermoelectric generators (TEGs) exploit the temperature difference between the skin (~32–34°C) and ambient air to generate voltage. Advances in flexible thermoelectric materials, such as bismuth telluride nanowires and organic polymers, have increased the efficiency of wearable TEGs to power densities of 20–50 µW/cm². While not enough to run an entire artificial pancreas alone, TEGs can supplement battery power, extending device run time by 20–30%. Researchers at MIT have demonstrated prototypes that integrate TEG arrays into a soft silicone patch, achieving comfortable contact and stable output. The biggest limitation is the minimal temperature gradient on a well-clothed body; performance improves in cooler environments or when the air temperature differs significantly from skin temperature.

Biofuel Cells

A more futuristic approach uses enzymes or microorganisms to generate electricity from glucose or lactate present in sweat or interstitial fluid. An enzymatic biofuel cell (EBFC) can theoretically produce up to 1 mW/cm² from physiological glucose levels. Because the fuel is continuously supplied by the body, the device could operate indefinitely without recharging. Practical challenges include enzyme stability over days and weeks, electrode fouling, and power output variability with metabolic state. Recent work from the Technical University of Munich has shown EBFCs that maintain over 80% of their initial power output for 30 days in vitro, and several companies are exploring integration into CGM sensors that could simultaneously power themselves and the insulin pump. However, no biofuel cell is yet approved for use in a medical device, and regulatory pathways are being established.

Wireless Charging for Seamless Daily Use

Inductive wireless charging has become standard in smartphones and is now being adapted for medical wearables. For artificial pancreas devices, wireless charging eliminates the need for exposed contacts, reducing infection risk and simplifying waterproofing. New resonant inductive coupling systems can charge through several millimeters of skin contact layer, allowing the user to recharge their device simply by placing it on a pad for 30 to 60 minutes each day. Some research groups are exploring resonant wireless power transfer (WPT) at higher frequencies (6.78 MHz) to achieve greater spatial freedom, so the device does not need to be precisely aligned. Additionally, the concept of over-the-air charging using low-power radio frequency (RF) energy is being tested, though efficiency is very low (well under 1%) and unlikely to provide meaningful power for an active pump. Nonetheless, even a limited RF trickle charge can keep a backup supercapacitor topped off for emergency situations.

Solid-State Batteries: Higher Density and Intrinsic Safety

Solid-state batteries replace the liquid or polymer gel electrolyte with a ceramic or solid polymer electrolyte, enabling the use of lithium metal anodes for much higher energy density—potentially 300–400 Wh/L versus 200–250 Wh/L for conventional Li-ion. For wearable medical devices, the greatest advantage is safety: solid electrolytes are non-flammable and do not leak, eliminating the risk of thermal runaway that has plagued some consumer electronics. Companies such as Blue Solutions and QuantumScape are scaling production for automotive and consumer applications, but smaller form factors for wearables are also emerging. A solid-state battery the size of a credit card could power an artificial pancreas for two weeks or more. The major challenge is manufacturing cost and the need for high-temperature processing, though recent advancements in cold sintering and printed solid electrolytes are reducing these barriers. The first medical devices incorporating solid-state batteries are expected to receive regulatory clearance within 2–3 years.

Tangible Benefits for Patients and Clinical Outcomes

Each of these power innovations translates directly into improved user experience and health outcomes for people with diabetes. The most immediate benefit is extended device runtime. Current artificial pancreas systems often require users to recharge their pumps every 24 to 72 hours. Innovations like thin-film and solid-state batteries can extend that to 7–14 days or more, dramatically reducing the burden of daily charging routines. This convenience encourages consistent use, which is correlated with better glycemic control. A 2022 study in Diabetes Technology & Therapeutics found that users who charged their devices less than once a week had 12% more time in range (70–180 mg/dL) than those charging daily, likely due to fewer interruptions and reduced alarm fatigue.

Furthermore, reduced device size and weight made possible by flexible and high-energy-density batteries improves comfort and discretion. A thinner, lighter patch can be worn under clothing without bulging, reducing self-consciousness and improving adherence, particularly among adolescents and young adults. Advanced safety features enabled by solid-state and thin-film chemistries lower the risk of battery failure, swelling, or overheating, which are rare but concerning with conventional lithium-ion cells. Wireless charging eliminates the mechanical wear and contamination issues of ports, increasing device longevity and reducing recalls.

For patients with type 1 diabetes, the integration of energy harvesting could eventually lead to truly maintenance-free devices that never need to be removed for charging, enabling continuous closed-loop control without interruptions. This would be especially valuable during sleep, when users might otherwise remove a device to charge it and thus lose automated insulin delivery overnight. Studies show that even short breaks in closed-loop therapy can lead to glycemic excursions, so uninterrupted power is a clinical priority.

Remaining Challenges on the Path to Adoption

Despite exciting progress, several barriers must be overcome before these power innovations become standard in commercial artificial pancreas devices.

  • Manufacturing Scalability and Cost: Flexible batteries and solid-state cells require new production lines and materials that are currently more expensive than traditional Li-ion. For a medical device that may retail for hundreds of dollars, adding tens of dollars to the battery cost is a significant hurdle. Economies of scale in the consumer electronics and electric vehicle sectors will help bring costs down, but device-specific customizations (custom shape, biocompatible packaging) add premium.
  • Durability and Lifetime: Wearable medical devices must withstand daily wear and tear including bending, sweat, temperature extremes, and occasional impacts. Flexible batteries must maintain capacity for hundreds of cycles without cracking or delamination. Energy harvesters must resist moisture and corrosion. Accelerated aging tests suggest that current thin-film batteries can survive 1000+ bending cycles, but real-world validation over years of use is ongoing.
  • Regulatory Approval: Medical devices require rigorous testing for biocompatibility, safety, and electromagnetic compatibility (EMC). For energy harvesters that use thermoelectric or piezoelectric materials, new biocompatibility data must be generated. The U.S. Food and Drug Administration (FDA) and European notified bodies are establishing guidelines for flexible electronics, but each novel battery chemistry or wireless charging system requires a premarket approval or 510(k) submission with extensive documentation. The FDA has been proactive in providing pathways for artificial pancreas components, but energy-related submissions can still take 12–18 months.
  • User Acceptance and Integration: Even the best technology needs user buy-in. Some patients may be hesitant about charging a device wirelessly (perceived radiation concerns) or wearing a device with an energy harvester that feels warm or vibrates. Heating from wireless charging pads must be limited to avoid discomfort. Design teams must conduct human factors studies to ensure that the recharging ritual or maintenance-free operation aligns with real-world behaviors.
  • Environmental and Disposal Considerations: As with all batteries, end-of-life disposal is a concern. Thin-film batteries often use rare or toxic metals, though many manufacturers are moving toward recyclable or biodegradable materials. The industry must develop take-back programs and regulations to ensure proper recycling.

Looking Ahead: The Next Generation of Power-Aware Closed-Loop Systems

The trajectory of wearable power sources is toward intelligent systems that combine multiple energy sources and optimize consumption. For example, a future artificial pancreas might integrate a thin-film primary battery for baseline power, a solid-state rechargeable cell for peak loads, a TENG or TEG for trickle charging during activity, and wireless charging for topping up overnight. The device’s micro-controller could run machine learning algorithms to predict power demand based on the user’s activity patterns and adjust insulin delivery scheduling to align with available energy. This power-aware closed-loop control represents a convergence of power electronics, materials science, and AI.

Emerging technologies also include supercapacitors with high power density for burst delivery during boluses, printed batteries that can be manufactured using roll-to-roll processes similar to newspaper printing, and flexible solar cells that can harvest ambient indoor light (though at very low power). Researchers at Stanford University recently demonstrated a self-powered biosensor that uses a glucose biofuel cell to run both the sensor and a wireless transmitter, suggesting a possible future where an artificial pancreas requires no external power source at all.

Several start-ups are already commercializing flexible medical batteries. Enfucell produces printed flexible batteries used in wearable medical patches, and Cambridge Nanosystems is developing graphene-based supercapacitors. Major medical device companies like Medtronic, Insulet, and Tandem Diabetes Care are actively investing in next-generation power solutions, as evidenced by recent patent filings and partnerships with battery startups. The market for wearable medical device batteries is projected to exceed $5 billion by 2028, with artificial pancreas systems representing a key growth segment.

Conclusion

Innovations in wearable power sources are not merely incremental improvements—they are foundational enablers for the next wave of artificial pancreas devices. By delivering longer run times, smaller form factors, inherent safety, and reduced user burden, technologies such as flexible thin-film batteries, energy harvesting, wireless charging, and solid-state cells are transforming what is possible in the management of diabetes. As these power solutions mature and gain regulatory approval, they will allow individuals with diabetes to experience truly continuous, worry-free automated insulin delivery. The result will be not only better glycemic outcomes but also a meaningful improvement in quality of life—freeing users from the constant anxiety of device charging and battery failure. The future of artificial pancreas systems is bright, and it is powered by innovation.